EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment

Helal F Hetta iD, Hashim M Aljohani iD, Nizar Sirag iD, Hassabelrasoul Elfadil iD, Ayman Salama iD, Rand Al-Twalhy, Danah Alanazi, Manal D Al-Johani, Jumanah H Albalawi, Rinad M Al-Otaibi, Raghad A Alsharif iD, Reem Sayad iD

Pharmaceuticals · 16.04.2025 · 18 (4) · 585

DOI: 10.3390/ph18040585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 16.04.2025. Verfasst von Helal F Hetta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of T…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anlotinib, a novel receptor tyrosine kinase inhibitor that is taken orally, targets several RTKs and is authorized as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Anlotinib is also used in combination with immunotherapy or chemotherapy for advanced NSCLC. We aimed to explore the efficacy and safety of anlotinib-based regimens in NSCLC treatment, focusing on combination therapies. We also addressed challenges that hinder oncologists from using it, such as toxicity and resistance mechanisms. A systematic approach involves searching the National Institute of Health PubMed, Scopus, MedLine, and Web of Science databases up to April 2024. Relevant studies were identified and analyzed for their methodologies, outcomes, and patient characteristics. Findings revealed that numerous effective combination regimens, such as anlotinib with platinum-based chemotherapy and anlotinib combined with PD-1 blockades, have shown positive results in terms of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). On the other hand, NSCLC treatment faces hurdles due to drug resistance and its toxicity profile. These challenges underscore the need for continued research and optimization of treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

a novel multi-targeting tyrosine kinase inhibitoranlotiniblung carcinomanon-small cell lung cancer(NSCLC)novel targeted drug

Autor:innen und Institutionen

  • Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madina 41477, Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45221, USA.
  • Division of Pharmacognosy, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
  • Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
  • PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.

ORCID-Profile: Helal F Hetta, Hashim M Aljohani, Nizar Sirag, Hassabelrasoul Elfadil, Ayman Salama, Raghad A Alsharif, Reem Sayad

Zitieren

APA

Hetta, H. F., Aljohani, H. M., Sirag, N., Elfadil, H., Salama, A., Al-Twalhy, R., Alanazi, D., Al-Johani, M. D., Albalawi, J. H., Al-Otaibi, R. M., Alsharif, R. A., & Sayad, R. (2025). Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment. Pharmaceuticals, 18(4), 585. https://doi.org/10.3390/ph18040585

Vancouver

Hetta HF, Aljohani HM, Sirag N, Elfadil H, Salama A, Al-Twalhy R, et al. Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment. Pharmaceuticals. 2025;18(4):585. doi:10.3390/ph18040585

BibTeX
@article{Hetta2025,
  author = {Hetta, Helal F and Aljohani, Hashim M and Sirag, Nizar and Elfadil, Hassabelrasoul and Salama, Ayman and Al-Twalhy, Rand and Alanazi, Danah and Al-Johani, Manal D and Albalawi, Jumanah H and Al-Otaibi, Rinad M and Alsharif, Raghad A and Sayad, Reem},
  title = {Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {4},
  pages = {585},
  doi = {10.3390/ph18040585}
}
Kostenlos starten →